{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:34:59Z","timestamp":1790998499465,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>We report results of a\u00a0multicenter prospective single-arm phase\u00a0II trial (ARO-2013-04, NCT01948726) of moderately accelerated hypofractionated radiotherapy with a\u00a0simultaneous integrated boost (SIB) in patients with breast cancer receiving adjuvant radiotherapy after breast-conserving surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The eligibility criteria included unifocal breast cancer with an indication for adjuvant radiotherapy to the whole breast and boost radiotherapy to the tumor bed. The whole breast received a\u00a0dose of 40\u202fGy and the tumor bed a\u00a0total dose of 48\u202fGy in 16\u00a0fractions of 2.5 and 3\u202fGy, respectively. Radiotherapy could be given either as 3D\u00a0conformal RT (3D-CRT) or as intensity-modulated radiotherapy (IMRT). The study was designed as a\u00a0prospective single-arm trial to evaluate the acute toxicity of the treatment regimen. The study hypothesis was that the frequency of acute skin reaction grade \u22652 would be 20% or less.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From November 2013 through July 2014, 149\u00a0patients were recruited from 12\u00a0participating centers. Six patients were excluded, leaving 143\u00a0patients for analysis. Eighty-four patients (58.7%) were treated with 3D-CRT and 59 (41.3%) with IMRT. Adherence to the treatment protocol was high. The rate of grade \u22652 skin toxicity was 14.7% (95% confidence interval 9.8\u201321.4%). The most frequent grade\u00a03 toxicity (11%) was hot flashes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrated low toxicity of and high treatment adherence to hypofractionated adjuvant radiotherapy with SIB in a\u00a0multicenter prospective trial, although the primary hypothesis was not met.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-020-01689-7","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T15:04:17Z","timestamp":1601564657000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a\u00a0prospective trial"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-5416","authenticated-orcid":false,"given":"David","family":"Krug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Krockenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Vonthein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Boicev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"W\u00fcrschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Weinstrauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Eilf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"H\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dinges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Piefel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Dellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Dunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"CD003860","DOI":"10.1002\/14651858.CD003860.pub4","volume":"7","author":"BE Hickey","year":"2016","unstructured":"Hickey\u00a0BE, James\u00a0ML, Lehman\u00a0M et\u00a0al (2016) Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev 7:CD3860. https:\/\/doi.org\/10.1002\/14651858.CD003860.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland\u00a0JS, Owen\u00a0JR, Dewar\u00a0JA et al (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14:1086\u20131094. https:\/\/doi.org\/10.1016\/S1470-2045(13)70386-3","journal-title":"Lancet Oncol"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1470-2045(06)70699-4","volume":"7","author":"JR Owen","year":"2006","unstructured":"Owen\u00a0JR, Ashton\u00a0A, Bliss\u00a0JM et al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a\u00a0randomised trial. Lancet Oncol 7:467\u2013471. https:\/\/doi.org\/10.1016\/S1470-2045(06)70699-4","journal-title":"Lancet Oncol"},{"key":"1689_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00317","author":"SF Shaitelman","year":"2018","unstructured":"Shaitelman\u00a0SF, Lei\u00a0X, Thompson\u00a0A et al (2018) Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a\u00a0randomized, noninferiority clinical trial. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.18.00317","journal-title":"J Clin Oncol"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13014-015-0452-2","volume":"10","author":"MMOM Aly","year":"2015","unstructured":"Aly\u00a0MMOM, Glatting\u00a0G, Jahnke\u00a0L et\u00a0al (2015) Comparison of breast simultaneous integrated boost (SIB) radiotherapy techniques. Radiat Oncol 10:139. https:\/\/doi.org\/10.1186\/s13014-015-0452-2","journal-title":"Radiat Oncol"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/827475","volume":"2014","author":"H Van Parijs","year":"2014","unstructured":"Van Parijs\u00a0H, Reynders\u00a0T, Heuninckx\u00a0K et\u00a0al (2014) Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost. Biomed Res Int 2014:1\u20138. https:\/\/doi.org\/10.1155\/2014\/827475","journal-title":"Biomed Res Int"},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1748-717X-9-36","volume":"9","author":"H Van Parijs","year":"2014","unstructured":"Van Parijs\u00a0H, Reynders\u00a0T, Heuninckx\u00a0K et al (2014) Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery. Radiat Oncol 9:36\u201337. https:\/\/doi.org\/10.1186\/1748-717X-9-36","journal-title":"Radiat Oncol"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1016\/j.ijrobp.2012.01.050","volume":"83","author":"EJ Bantema-Joppe","year":"2012","unstructured":"Bantema-Joppe\u00a0EJ, Schilstra\u00a0C, de Bock\u00a0GH et al (2012) Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30\u00a0months\u2019 follow-up. Int J Radiat Oncol Biol Phys 83:e471\u2013e477. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.01.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000501000","volume":"14","author":"N Ditsch","year":"2019","unstructured":"Ditsch\u00a0N, Untch\u00a0M, Thill\u00a0M et\u00a0al (2019) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2019. Breast Care 14:224\u2013245. https:\/\/doi.org\/10.1159\/000501000","journal-title":"Breast Care"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1055\/a-0646-4630","volume":"78","author":"A W\u00f6ckel","year":"2018","unstructured":"W\u00f6ckel\u00a0A, Festl\u00a0J, St\u00fcber\u00a0T et al (2018) Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer. Guideline of the DGGG and the DKG (S3-level, AWMF registry number 032\/045OL, December 2017) \u2013 Part 2 with recommendations for the therapy of primary, recurrent and advanced breast cancer. Geburtshilfe Frauenheilkd 78:1056\u20131088. https:\/\/doi.org\/10.1055\/a-0646-4630","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clbc.2011.09.002","volume":"12","author":"M Chadha","year":"2012","unstructured":"Chadha\u00a0M, Vongtama\u00a0D, Friedmann\u00a0P et al (2012) Comparative acute toxicity from whole breast irradiation using 3\u2011week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer 12:57\u201362. https:\/\/doi.org\/10.1016\/j.clbc.2011.09.002","journal-title":"Clin Breast Cancer"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12032-017-1020-4","volume":"34","author":"D Cante","year":"2017","unstructured":"Cante\u00a0D, Petrucci\u00a0E, Sciacero\u00a0P et al (2017) Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer. Med Oncol 34:152. https:\/\/doi.org\/10.1007\/s12032-017-1020-4","journal-title":"Med Oncol"},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00066-014-0658-5","volume":"190","author":"K Dellas","year":"2014","unstructured":"Dellas\u00a0K, Vonthein\u00a0R, Zimmer\u00a0J et al (2014) Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01). Strahlenther Onkol 190:646\u2013653. https:\/\/doi.org\/10.1007\/s00066-014-0658-5","journal-title":"Strahlenther Onkol"},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13014-016-0701-z","volume":"11","author":"F De Rose","year":"2016","unstructured":"De Rose\u00a0F, Fogliata\u00a0A, Franceschini\u00a0D et al (2016) Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2\u2011year toxicity and clinical results. Radiat Oncol 11:120\u2013129. https:\/\/doi.org\/10.1186\/s13014-016-0701-z","journal-title":"Radiat Oncol"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2016.12.023","volume":"122","author":"L Paelinck","year":"2017","unstructured":"Paelinck\u00a0L, Gulyban\u00a0A, Lakosi\u00a0F et\u00a0al (2017) Does an integrated boost increase acute toxicity in prone hypofractionated breast irradiation? A randomized controlled trial. Radiother Oncol 122:30\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2016.12.023","journal-title":"Radiother Oncol"},{"key":"1689_CR16","unstructured":"AGO Leitlinienkommission Mamma (2020) Leitlinien der AGO-Kommission Mamma. https:\/\/www.ago-online.de\/leitlinien-empfehlungen\/leitlinien-empfehlungen\/kommission-mamma. Accessed 9 Aug 2020"},{"key":"1689_CR17","unstructured":"Leitlinienprogramm Onkologie (2012) Interdisziplin\u00e4re S3-Leitlinie f\u00fcr die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Mammakarzinom\/S3-Brustkrebs-v2012-OL-Langversion.pdf. Accessed 18 Aug 2020"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00066-019-01495-w","volume":"195","author":"MN Duma","year":"2019","unstructured":"Duma\u00a0MN, Baumann\u00a0R, Budach\u00a0W et al (2019) Heart-sparing radiotherapy techniques in breast cancer patients: a\u00a0recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO). Strahlenther Onkol 195:861\u2013871. https:\/\/doi.org\/10.1007\/s00066-019-01495-w","journal-title":"Strahlenther Onkol"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00066-018-1378-z","volume":"88","author":"MD Piroth","year":"2018","unstructured":"Piroth\u00a0MD, Baumann\u00a0R, Budach\u00a0W et\u00a0al (2018) Heart toxicity from breast cancer radiotherapy: current findings, assessment, and prevention. Strahlenther Onkol 88:1659\u20131612. https:\/\/doi.org\/10.1007\/s00066-018-1378-z","journal-title":"Strahlenther Onkol"},{"key":"1689_CR20","unstructured":"National Cancer Institute, National Institutes of Health, Department of Health (2010) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 18 Aug 2020"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson\u00a0NK, Ahmedzai\u00a0S, Bergman\u00a0B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a\u00a0quality-of-life instrument for use in international clinical trials in oncology. Jnci J Natl Cancer Inst 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"Jnci J Natl Cancer Inst"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers\u00a0MA, Groenvold\u00a0M, Arraras\u00a0JI et al (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a\u00a0three-country field study. J\u00a0Clin Oncol 14:2756\u20132768. https:\/\/doi.org\/10.1200\/JCO.1996.14.10.2756","journal-title":"J Clin Oncol"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","volume":"5","author":"JR Harris","year":"1979","unstructured":"Harris\u00a0JR, Levene\u00a0MB, Svensson\u00a0G, Hellman\u00a0S (1979) Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys 5:257\u2013261. https:\/\/doi.org\/10.1016\/0360-3016(79)90729-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13014-016-0590-1","volume":"11","author":"MMOM Aly","year":"2016","unstructured":"Aly\u00a0MMOM, Abo-Madyan\u00a0Y, Jahnke\u00a0L et al (2016) Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH). Radiat Oncol 11:16. https:\/\/doi.org\/10.1186\/s13014-016-0590-1","journal-title":"Radiat Oncol"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00066-019-01555-1","volume":"378","author":"K Balaji","year":"2019","unstructured":"Balaji\u00a0K, Balaji\u00a0Subramanian S, Sathiya\u00a0K et al (2019) Hybrid planning techniques for hypofractionated whole-breast irradiation using flattening filter-free beams. Strahlenther Onkol 378:1707\u20131710. https:\/\/doi.org\/10.1007\/s00066-019-01555-1","journal-title":"Strahlenther Onkol"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.radonc.2013.08.037","volume":"108","author":"EJ Bantema-Joppe","year":"2013","unstructured":"Bantema-Joppe\u00a0EJ, Vredeveld\u00a0EJ, de Bock\u00a0GH et al (2013) Five year outcomes of hypofractionated simultaneous integrated boost irradiation in breast conserving therapy; patterns of recurrence. Radiother Oncol 108:269\u2013272. https:\/\/doi.org\/10.1016\/j.radonc.2013.08.037","journal-title":"Radiother Oncol"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1748-717X-7-80","volume":"7","author":"H Van Parijs","year":"2012","unstructured":"Van Parijs\u00a0H, Miedema\u00a0G, Vinh-Hung\u00a0V et al (2012) Short course radiotherapy with simultaneous integrated boost for stage I\u2013II breast cancer, early toxicities of a\u00a0randomized clinical trial. Radiat Oncol 7:80\u201310. https:\/\/doi.org\/10.1186\/1748-717X-7-80","journal-title":"Radiat Oncol"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.radonc.2020.02.001","volume":"146","author":"G Fastner","year":"2020","unstructured":"Fastner\u00a0G, Reitsamer\u00a0R, Urba\u0144ski\u00a0B et al (2020) Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): first results of a\u00a0prospective multicenter trial (NCT01343459). Radiother Oncol 146:136\u2013142. https:\/\/doi.org\/10.1016\/j.radonc.2020.02.001","journal-title":"Radiother Oncol"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00066-017-1213-y","volume":"194","author":"S Corradini","year":"2018","unstructured":"Corradini\u00a0S, Ballhausen\u00a0H, Weingandt\u00a0H et al (2018) Left-sided breast cancer and risks of secondary lung cancer and ischemic heart disease: effects of modern radiotherapy techniques. Strahlenther Onkol 194:196\u2013205. https:\/\/doi.org\/10.1007\/s00066-017-1213-y","journal-title":"Strahlenther Onkol"},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00066-018-1384-1","volume":"195","author":"C Simonetto","year":"2019","unstructured":"Simonetto\u00a0C, Rennau\u00a0H, Remmele\u00a0J et al (2019) Exposure of remote organs and associated cancer risks from tangential and multi-field breast cancer radiotherapy. Strahlenther Onkol 195:32\u201342. https:\/\/doi.org\/10.1007\/s00066-018-1384-1","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01689-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-020-01689-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01689-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:10:05Z","timestamp":1633050605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-020-01689-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01689-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"D.\u00a0Krug has received honoraria from Merck Sharp & Dome, outside of the submitted work. R.\u00a0Baumann, K.\u00a0Krockenberger, R.\u00a0Vonthein, A.\u00a0Schreiber, A.\u00a0Boicev, F.\u00a0W\u00fcrschmidt, E.\u00a0Weinstrauch, K.\u00a0Eilf, P.\u00a0Andreas, U.\u00a0H\u00f6ller, S.\u00a0Dinges, K.\u00a0Piefel, J.\u00a0Zimmer, K.\u00a0Dellas, and J.\u00a0Dunst declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the University of L\u00fcbeck (leading ethics committee, file number 13-071) as well as local ethics committees at the participating sites. All patients provided written informed consent before enrolment in the clinical trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}